42268 Real-World Utilization of Adalimumab Biosimilar (ABP 501) in Patients with Psoriasis in Europe

Ran Jin,Eleanor Wrest,James Haughton,James Piercy,Rachel Meadows,Waldemar Radziszewski

Journal of the American Academy of Dermatology（2023）

引用 0|浏览4

暂无评分

摘要

Background: ABP 501 is the first EMA- and FDA-approved adalimumab (ADA) biosimilar for treating certain immune-mediated inflammatory diseases including psoriasis (PsO). Real-world data of its utilization are limited.

查看译文

关键词

Medication Adherence

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要